BIIB122
Sponsors
Biogen Idec Research Limited, Denali Therapeutics Inc., Biogen
Conditions
Healthy VolunteerParkinson DiseaseParkinson's DiseaseParkinson’s disease
Phase 1
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
CompletedNCT05229562
Start: 2022-02-17End: 2022-09-07Updated: 2023-04-18
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
CompletedNCT06264440
Start: 2024-02-12End: 2024-06-18Updated: 2024-07-19
Phase 2
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Active, not recruitingNCT05348785
Start: 2022-04-19End: 2026-03-09Updated: 2025-10-23
283PD201 (LUMA): A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease
Active, not recruitingCTIS2023-505645-12-00
Start: 2022-11-28Target: 311Updated: 2026-01-09
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD)
RecruitingCTIS2024-513384-15-00
Start: 2025-02-13Target: 27Updated: 2024-12-05